Dimensional Fund Advisors LP Has $9.29 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Dimensional Fund Advisors LP raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 15.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,210,080 shares of the company's stock after buying an additional 163,880 shares during the quarter. Dimensional Fund Advisors LP owned 3.31% of iTeos Therapeutics worth $9,293,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ITOS. JPMorgan Chase & Co. increased its position in shares of iTeos Therapeutics by 342.7% in the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock valued at $15,888,000 after buying an additional 1,601,477 shares in the last quarter. Renaissance Technologies LLC grew its stake in iTeos Therapeutics by 56.1% in the fourth quarter. Renaissance Technologies LLC now owns 837,200 shares of the company's stock valued at $6,430,000 after acquiring an additional 300,800 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of iTeos Therapeutics during the fourth quarter worth about $1,159,000. Trexquant Investment LP raised its position in shares of iTeos Therapeutics by 267.2% during the fourth quarter. Trexquant Investment LP now owns 179,966 shares of the company's stock worth $1,382,000 after purchasing an additional 130,960 shares during the period. Finally, Peapod Lane Capital LLC bought a new position in shares of iTeos Therapeutics during the 4th quarter valued at about $836,000. Institutional investors own 97.16% of the company's stock.

iTeos Therapeutics Stock Down 0.3 %

Shares of ITOS stock opened at $6.68 on Friday. iTeos Therapeutics, Inc. has a 12 month low of $4.80 and a 12 month high of $18.70. The company's fifty day simple moving average is $6.55 and its 200-day simple moving average is $7.44. The firm has a market cap of $255.67 million, a PE ratio of -2.12 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.14. On average, equities analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ITOS has been the topic of several research analyst reports. Wedbush restated an "outperform" rating and set a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Wells Fargo & Company cut their price objective on shares of iTeos Therapeutics from $17.00 to $16.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. JPMorgan Chase & Co. lowered their target price on iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating for the company in a report on Thursday, March 6th. Finally, HC Wainwright restated a "buy" rating and issued a $46.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 6th.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.